Netarsudil	B:C1254351
Increases	O
Outflow	O
Facility	I:C0430894
in	O
Human	O
Eyes	O
Through	O
Multiple	O
Mechanisms	O
.	O

Netarsudil	O
Increases	O
Outflow	B:C0430894
Facility	I:C0430894
in	O
Human	O
Eyes	O
Through	O
Multiple	O
Mechanisms	O
.	O

Netarsudil	O
Increases	O
Outflow	O
Facility	I:C0430894
in	O
Human	B:C0086418
Eyes	O
Through	O
Multiple	O
Mechanisms	O
.	O

Netarsudil	O
Increases	O
Outflow	O
Facility	I:C0430894
in	O
Human	O
Eyes	B:C0015392
Through	O
Multiple	O
Mechanisms	O
.	O

Netarsudil	B:C1254351
is	O
a	O
Rho	O
kinase	I:C0033671
/	I:C0033671
norepinephrine	I:C0033671
transporter	I:C0033671
inhibitor	I:C0033671
currently	O
in	O
phase	O
3	I:C0282461
clinical	I:C0282461
development	I:C0282461
for	O
glaucoma	O
treatment	O
.	O

Netarsudil	O
is	O
a	O
Rho	B:C0033671
kinase	I:C0033671
/	I:C0033671
norepinephrine	I:C0033671
transporter	I:C0033671
inhibitor	I:C0033671
currently	O
in	O
phase	O
3	I:C0282461
clinical	I:C0282461
development	I:C0282461
for	O
glaucoma	O
treatment	O
.	O

Netarsudil	O
is	O
a	O
Rho	O
kinase	I:C0033671
/	I:C0033671
norepinephrine	I:C0033671
transporter	I:C0033671
inhibitor	I:C0033671
currently	O
in	O
phase	B:C0282461
3	I:C0282461
clinical	I:C0282461
development	I:C0282461
for	O
glaucoma	O
treatment	O
.	O

Netarsudil	O
is	O
a	O
Rho	O
kinase	I:C0033671
/	I:C0033671
norepinephrine	I:C0033671
transporter	I:C0033671
inhibitor	I:C0033671
currently	O
in	O
phase	O
3	I:C0282461
clinical	I:C0282461
development	I:C0282461
for	O
glaucoma	B:C0017601
treatment	O
.	O

Netarsudil	O
is	O
a	O
Rho	O
kinase	I:C0033671
/	I:C0033671
norepinephrine	I:C0033671
transporter	I:C0033671
inhibitor	I:C0033671
currently	O
in	O
phase	O
3	I:C0282461
clinical	I:C0282461
development	I:C0282461
for	O
glaucoma	O
treatment	B:C0087111
.	O

We	O
investigated	O
the	O
effects	O
of	O
its	O
active	O
metabolite	B:C0870883
,	O
netarsudil	O
-	I:C1254351
M1	I:C1254351
,	O
on	O
outflow	O
facility	I:C0430894
(	O
C	O
)	O
,	O
outflow	O
hydrodynamics	O
,	O
and	O
morphology	O
of	O
the	O
conventional	O
outflow	O
pathway	O
in	O
enucleated	O
human	O
eyes	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
its	O
active	O
metabolite	O
,	O
netarsudil	B:C1254351
-	I:C1254351
M1	I:C1254351
,	O
on	O
outflow	O
facility	I:C0430894
(	O
C	O
)	O
,	O
outflow	O
hydrodynamics	O
,	O
and	O
morphology	O
of	O
the	O
conventional	O
outflow	O
pathway	O
in	O
enucleated	O
human	O
eyes	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
its	O
active	O
metabolite	O
,	O
netarsudil	O
-	I:C1254351
M1	I:C1254351
,	O
on	O
outflow	B:C0430894
facility	I:C0430894
(	O
C	O
)	O
,	O
outflow	O
hydrodynamics	O
,	O
and	O
morphology	O
of	O
the	O
conventional	O
outflow	O
pathway	O
in	O
enucleated	O
human	O
eyes	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
its	O
active	O
metabolite	O
,	O
netarsudil	O
-	I:C1254351
M1	I:C1254351
,	O
on	O
outflow	O
facility	I:C0430894
(	O
C	B:C0430894
)	O
,	O
outflow	O
hydrodynamics	O
,	O
and	O
morphology	O
of	O
the	O
conventional	O
outflow	O
pathway	O
in	O
enucleated	O
human	O
eyes	O
.	O

Paired	O
human	B:C0086418
eyes	O
(	O
n	O
=	O
5	O
)	O
were	O
perfused	O
with	O
either	O
0.3	O
μM	O
netarsudil	O
-	I:C1254351
M1	I:C1254351
or	O
vehicle	O
solution	I:C0042444
at	O
constant	O
pressure	O
(	O
15	O
mm	O
Hg	O
)	O
.	O

Paired	O
human	O
eyes	B:C0015392
(	O
n	O
=	O
5	O
)	O
were	O
perfused	O
with	O
either	O
0.3	O
μM	O
netarsudil	O
-	I:C1254351
M1	I:C1254351
or	O
vehicle	O
solution	I:C0042444
at	O
constant	O
pressure	O
(	O
15	O
mm	O
Hg	O
)	O
.	O

Paired	O
human	O
eyes	O
(	O
n	O
=	O
5	O
)	O
were	O
perfused	B:C0031001
with	O
either	O
0.3	O
μM	O
netarsudil	O
-	I:C1254351
M1	I:C1254351
or	O
vehicle	O
solution	I:C0042444
at	O
constant	O
pressure	O
(	O
15	O
mm	O
Hg	O
)	O
.	O

Paired	O
human	O
eyes	O
(	O
n	O
=	O
5	O
)	O
were	O
perfused	O
with	O
either	O
0.3	O
μM	O
netarsudil	B:C1254351
-	I:C1254351
M1	I:C1254351
or	O
vehicle	O
solution	I:C0042444
at	O
constant	O
pressure	O
(	O
15	O
mm	O
Hg	O
)	O
.	O

Paired	O
human	O
eyes	O
(	O
n	O
=	O
5	O
)	O
were	O
perfused	O
with	O
either	O
0.3	O
μM	O
netarsudil	O
-	I:C1254351
M1	I:C1254351
or	O
vehicle	B:C0042444
solution	I:C0042444
at	O
constant	O
pressure	O
(	O
15	O
mm	O
Hg	O
)	O
.	O

After	O
3	O
hours	O
,	O
fluorescent	B:C0026032
microspheres	I:C0026032
were	O
added	O
to	O
perfusion	O
media	O
to	O
trace	O
the	O
outflow	O
patterns	O
before	O
perfusion	O
-	O
fixation	O
.	O

After	O
3	O
hours	O
,	O
fluorescent	O
microspheres	I:C0026032
were	O
added	O
to	O
perfusion	B:C0031001
media	O
to	O
trace	O
the	O
outflow	O
patterns	O
before	O
perfusion	O
-	O
fixation	O
.	O

After	O
3	O
hours	O
,	O
fluorescent	O
microspheres	I:C0026032
were	O
added	O
to	O
perfusion	O
media	B:C0009924
to	O
trace	O
the	O
outflow	O
patterns	O
before	O
perfusion	O
-	O
fixation	O
.	O

After	O
3	O
hours	O
,	O
fluorescent	O
microspheres	I:C0026032
were	O
added	O
to	O
perfusion	O
media	O
to	O
trace	O
the	O
outflow	O
patterns	O
before	O
perfusion	B:C0031001
-	O
fixation	O
.	O

After	O
3	O
hours	O
,	O
fluorescent	O
microspheres	I:C0026032
were	O
added	O
to	O
perfusion	O
media	O
to	O
trace	O
the	O
outflow	O
patterns	O
before	O
perfusion	O
-	O
fixation	B:C0185023
.	O

The	O
percentage	O
effective	O
filtration	O
length	O
(	O
PEFL	O
)	O
was	O
calculated	O
from	O
the	O
measured	O
lengths	O
of	O
tracer	B:C1522485
distribution	O
in	O
the	O
trabecular	O
meshwork	I:C0040573
(	O
trabecular	O
meshwork	I:C0040573
)	O
,	O
episcleral	O
veins	I:C0226616
(	O
episcleral	O
veins	I:C0226616
)	O
,	O
and	O
along	O
the	O
inner	O
wall	O
(	O
IW	O
)	O
of	O
Schlemm	O
's	I:C0229108
canal	I:C0229108
after	O
global	O
and	O
confocal	O
imaging	I:C0242842
.	O

The	O
percentage	O
effective	O
filtration	O
length	O
(	O
PEFL	O
)	O
was	O
calculated	O
from	O
the	O
measured	O
lengths	O
of	O
tracer	O
distribution	O
in	O
the	O
trabecular	B:C0040573
meshwork	I:C0040573
(	O
trabecular	O
meshwork	I:C0040573
)	O
,	O
episcleral	O
veins	I:C0226616
(	O
episcleral	O
veins	I:C0226616
)	O
,	O
and	O
along	O
the	O
inner	O
wall	O
(	O
IW	O
)	O
of	O
Schlemm	O
's	I:C0229108
canal	I:C0229108
after	O
global	O
and	O
confocal	O
imaging	I:C0242842
.	O

The	O
percentage	O
effective	O
filtration	O
length	O
(	O
PEFL	O
)	O
was	O
calculated	O
from	O
the	O
measured	O
lengths	O
of	O
tracer	O
distribution	O
in	O
the	O
trabecular	O
meshwork	I:C0040573
(	O
trabecular	B:C0040573
meshwork	I:C0040573
)	O
,	O
episcleral	O
veins	I:C0226616
(	O
episcleral	O
veins	I:C0226616
)	O
,	O
and	O
along	O
the	O
inner	O
wall	O
(	O
IW	O
)	O
of	O
Schlemm	O
's	I:C0229108
canal	I:C0229108
after	O
global	O
and	O
confocal	O
imaging	I:C0242842
.	O

The	O
percentage	O
effective	O
filtration	O
length	O
(	O
PEFL	O
)	O
was	O
calculated	O
from	O
the	O
measured	O
lengths	O
of	O
tracer	O
distribution	O
in	O
the	O
trabecular	O
meshwork	I:C0040573
(	O
trabecular	O
meshwork	I:C0040573
)	O
,	O
episcleral	B:C0226616
veins	I:C0226616
(	O
episcleral	O
veins	I:C0226616
)	O
,	O
and	O
along	O
the	O
inner	O
wall	O
(	O
IW	O
)	O
of	O
Schlemm	O
's	I:C0229108
canal	I:C0229108
after	O
global	O
and	O
confocal	O
imaging	I:C0242842
.	O

The	O
percentage	O
effective	O
filtration	O
length	O
(	O
PEFL	O
)	O
was	O
calculated	O
from	O
the	O
measured	O
lengths	O
of	O
tracer	O
distribution	O
in	O
the	O
trabecular	O
meshwork	I:C0040573
(	O
trabecular	O
meshwork	I:C0040573
)	O
,	O
episcleral	O
veins	I:C0226616
(	O
episcleral	B:C0226616
veins	I:C0226616
)	O
,	O
and	O
along	O
the	O
inner	O
wall	O
(	O
IW	O
)	O
of	O
Schlemm	O
's	I:C0229108
canal	I:C0229108
after	O
global	O
and	O
confocal	O
imaging	I:C0242842
.	O

The	O
percentage	O
effective	O
filtration	O
length	O
(	O
PEFL	O
)	O
was	O
calculated	O
from	O
the	O
measured	O
lengths	O
of	O
tracer	O
distribution	O
in	O
the	O
trabecular	O
meshwork	I:C0040573
(	O
trabecular	O
meshwork	I:C0040573
)	O
,	O
episcleral	O
veins	I:C0226616
(	O
episcleral	O
veins	I:C0226616
)	O
,	O
and	O
along	O
the	O
inner	O
wall	O
(	O
IW	O
)	O
of	O
Schlemm	B:C0229108
's	I:C0229108
canal	I:C0229108
after	O
global	O
and	O
confocal	O
imaging	I:C0242842
.	O

The	O
percentage	O
effective	O
filtration	O
length	O
(	O
PEFL	O
)	O
was	O
calculated	O
from	O
the	O
measured	O
lengths	O
of	O
tracer	O
distribution	O
in	O
the	O
trabecular	O
meshwork	I:C0040573
(	O
trabecular	O
meshwork	I:C0040573
)	O
,	O
episcleral	O
veins	I:C0226616
(	O
episcleral	O
veins	I:C0226616
)	O
,	O
and	O
along	O
the	O
inner	O
wall	O
(	O
IW	O
)	O
of	O
Schlemm	O
's	I:C0229108
canal	I:C0229108
after	O
global	O
and	O
confocal	B:C0242842
imaging	I:C0242842
.	O

Morphologic	B:C1260954
changes	I:C1260954
along	O
the	O
trabecular	O
outflow	O
pathway	O
were	O
investigated	O
by	O
confocal	O
,	O
light	O
,	O
and	O
electron	O
microscopy	I:C0026019
.	O

Morphologic	O
changes	I:C1260954
along	O
the	O
trabecular	B:C0040573
outflow	O
pathway	O
were	O
investigated	O
by	O
confocal	O
,	O
light	O
,	O
and	O
electron	O
microscopy	I:C0026019
.	O

Morphologic	O
changes	I:C1260954
along	O
the	O
trabecular	O
outflow	O
pathway	O
were	O
investigated	O
by	O
confocal	B:C0242842
,	O
light	O
,	O
and	O
electron	O
microscopy	I:C0026019
.	O

Morphologic	O
changes	I:C1260954
along	O
the	O
trabecular	O
outflow	O
pathway	O
were	O
investigated	O
by	O
confocal	O
,	O
light	B:C0430389
,	O
and	O
electron	O
microscopy	I:C0026019
.	O

Morphologic	O
changes	I:C1260954
along	O
the	O
trabecular	O
outflow	O
pathway	O
were	O
investigated	O
by	O
confocal	O
,	O
light	O
,	O
and	O
electron	B:C0026019
microscopy	I:C0026019
.	O

Perfusion	B:C0031001
with	O
netarsudil	O
-	I:C1254351
M1	I:C1254351
significantly	O
increased	O
C	O
when	O
compared	O
to	O
baseline	O
(	O
51	O
%	O
,	O
P	O
<	O
0.01	O
)	O
and	O
to	O
paired	O
controls	O
(	O
102	O
%	O
,	O
P	O
<	O
0.01	O
)	O
,	O
as	O
well	O
as	O
significantly	O
increased	O
PEFL	O
in	O
both	O
IW	O
(	O
P	O
<	O
0.05	O
)	O
and	O
episcleral	O
veins	I:C0226616
(	O
P	O
<	O
0.01	O
)	O
.	O

Perfusion	O
with	O
netarsudil	B:C1254351
-	I:C1254351
M1	I:C1254351
significantly	O
increased	O
C	O
when	O
compared	O
to	O
baseline	O
(	O
51	O
%	O
,	O
P	O
<	O
0.01	O
)	O
and	O
to	O
paired	O
controls	O
(	O
102	O
%	O
,	O
P	O
<	O
0.01	O
)	O
,	O
as	O
well	O
as	O
significantly	O
increased	O
PEFL	O
in	O
both	O
IW	O
(	O
P	O
<	O
0.05	O
)	O
and	O
episcleral	O
veins	I:C0226616
(	O
P	O
<	O
0.01	O
)	O
.	O

Perfusion	O
with	O
netarsudil	O
-	I:C1254351
M1	I:C1254351
significantly	O
increased	O
C	B:C0430894
when	O
compared	O
to	O
baseline	O
(	O
51	O
%	O
,	O
P	O
<	O
0.01	O
)	O
and	O
to	O
paired	O
controls	O
(	O
102	O
%	O
,	O
P	O
<	O
0.01	O
)	O
,	O
as	O
well	O
as	O
significantly	O
increased	O
PEFL	O
in	O
both	O
IW	O
(	O
P	O
<	O
0.05	O
)	O
and	O
episcleral	O
veins	I:C0226616
(	O
P	O
<	O
0.01	O
)	O
.	O

Perfusion	O
with	O
netarsudil	O
-	I:C1254351
M1	I:C1254351
significantly	O
increased	O
C	O
when	O
compared	O
to	O
baseline	O
(	O
51	O
%	O
,	O
P	O
<	O
0.01	O
)	O
and	O
to	O
paired	O
controls	O
(	O
102	O
%	O
,	O
P	O
<	O
0.01	O
)	O
,	O
as	O
well	O
as	O
significantly	O
increased	O
PEFL	O
in	O
both	O
IW	O
(	O
P	O
<	O
0.05	O
)	O
and	O
episcleral	B:C0226616
veins	I:C0226616
(	O
P	O
<	O
0.01	O
)	O
.	O

In	O
treated	O
eyes	B:C0015392
,	O
PEFL	O
was	O
significantly	O
higher	O
in	O
episcleral	O
veins	I:C0226616
than	O
in	O
the	O
IW	O
(	O
P	O
<	O
0.01	O
)	O
and	O
was	O
associated	O
with	O
increased	O
cross-sectional	O
area	I:C0205146
of	O
episcleral	O
veins	I:C0226616
(	O
P	O
<	O
0.01	O
)	O
.	O

In	O
treated	O
eyes	O
,	O
PEFL	O
was	O
significantly	O
higher	O
in	O
episcleral	B:C0226616
veins	I:C0226616
than	O
in	O
the	O
IW	O
(	O
P	O
<	O
0.01	O
)	O
and	O
was	O
associated	O
with	O
increased	O
cross-sectional	O
area	I:C0205146
of	O
episcleral	O
veins	I:C0226616
(	O
P	O
<	O
0.01	O
)	O
.	O

In	O
treated	O
eyes	O
,	O
PEFL	O
was	O
significantly	O
higher	O
in	O
episcleral	O
veins	I:C0226616
than	O
in	O
the	O
IW	O
(	O
P	O
<	O
0.01	O
)	O
and	O
was	O
associated	O
with	O
increased	O
cross-sectional	B:C0205146
area	I:C0205146
of	O
episcleral	O
veins	I:C0226616
(	O
P	O
<	O
0.01	O
)	O
.	O

In	O
treated	O
eyes	O
,	O
PEFL	O
was	O
significantly	O
higher	O
in	O
episcleral	O
veins	I:C0226616
than	O
in	O
the	O
IW	O
(	O
P	O
<	O
0.01	O
)	O
and	O
was	O
associated	O
with	O
increased	O
cross-sectional	O
area	I:C0205146
of	O
episcleral	B:C0226616
veins	I:C0226616
(	O
P	O
<	O
0.01	O
)	O
.	O

Percentage	O
effective	O
filtration	O
length	O
in	O
episcleral	B:C0226616
veins	I:C0226616
positively	O
correlated	O
with	O
the	O
percentage	O
change	O
in	O
C	O
(	O
R2	O
=	O
0.58	O
,	O
P	O
=	O
0.01	O
)	O
.	O

Percentage	O
effective	O
filtration	O
length	O
in	O
episcleral	O
veins	I:C0226616
positively	O
correlated	O
with	O
the	O
percentage	O
change	O
in	O
C	B:C0430894
(	O
R2	O
=	O
0.58	O
,	O
P	O
=	O
0.01	O
)	O
.	O

A	O
significant	O
increase	O
in	O
juxtacanalicular	B:C0009780
connective	I:C0009780
tissue	I:C0009780
(	O
juxtacanalicular	O
connective	I:C0009780
tissue	I:C0009780
)	O
thickness	O
(	O
P	O
<	O
0.05	O
)	O
was	O
found	O
in	O
treated	O
eyes	O
compared	O
to	O
controls	O
.	O

A	O
significant	O
increase	O
in	O
juxtacanalicular	O
connective	I:C0009780
tissue	I:C0009780
(	O
juxtacanalicular	B:C0009780
connective	I:C0009780
tissue	I:C0009780
)	O
thickness	O
(	O
P	O
<	O
0.05	O
)	O
was	O
found	O
in	O
treated	O
eyes	O
compared	O
to	O
controls	O
.	O

A	O
significant	O
increase	O
in	O
juxtacanalicular	O
connective	I:C0009780
tissue	I:C0009780
(	O
juxtacanalicular	O
connective	I:C0009780
tissue	I:C0009780
)	O
thickness	O
(	O
P	O
<	O
0.05	O
)	O
was	O
found	O
in	O
treated	O
eyes	B:C0015392
compared	O
to	O
controls	O
.	O

Netarsudil	B:C1254351
acutely	O
increased	O
C	O
by	O
expansion	O
of	O
the	O
juxtacanalicular	O
connective	I:C0009780
tissue	I:C0009780
and	O
dilating	O
the	O
episcleral	O
veins	I:C0226616
,	O
which	O
led	O
to	O
redistribution	O
of	O
aqueous	O
outflow	O
through	O
a	O
larger	O
area	I:C0205146
of	O
the	O
IW	O
and	O
episcleral	O
veins	I:C0226616
.	O

Netarsudil	O
acutely	O
increased	O
C	B:C0430894
by	O
expansion	O
of	O
the	O
juxtacanalicular	O
connective	I:C0009780
tissue	I:C0009780
and	O
dilating	O
the	O
episcleral	O
veins	I:C0226616
,	O
which	O
led	O
to	O
redistribution	O
of	O
aqueous	O
outflow	O
through	O
a	O
larger	O
area	I:C0205146
of	O
the	O
IW	O
and	O
episcleral	O
veins	I:C0226616
.	O

Netarsudil	O
acutely	O
increased	O
C	O
by	O
expansion	O
of	O
the	O
juxtacanalicular	B:C0009780
connective	I:C0009780
tissue	I:C0009780
and	O
dilating	O
the	O
episcleral	O
veins	I:C0226616
,	O
which	O
led	O
to	O
redistribution	O
of	O
aqueous	O
outflow	O
through	O
a	O
larger	O
area	I:C0205146
of	O
the	O
IW	O
and	O
episcleral	O
veins	I:C0226616
.	O

Netarsudil	O
acutely	O
increased	O
C	O
by	O
expansion	O
of	O
the	O
juxtacanalicular	O
connective	I:C0009780
tissue	I:C0009780
and	O
dilating	O
the	O
episcleral	B:C0226616
veins	I:C0226616
,	O
which	O
led	O
to	O
redistribution	O
of	O
aqueous	O
outflow	O
through	O
a	O
larger	O
area	I:C0205146
of	O
the	O
IW	O
and	O
episcleral	O
veins	I:C0226616
.	O

Netarsudil	O
acutely	O
increased	O
C	O
by	O
expansion	O
of	O
the	O
juxtacanalicular	O
connective	I:C0009780
tissue	I:C0009780
and	O
dilating	O
the	O
episcleral	O
veins	I:C0226616
,	O
which	O
led	O
to	O
redistribution	O
of	O
aqueous	O
outflow	O
through	O
a	O
larger	B:C0205146
area	I:C0205146
of	O
the	O
IW	O
and	O
episcleral	O
veins	I:C0226616
.	O

Netarsudil	O
acutely	O
increased	O
C	O
by	O
expansion	O
of	O
the	O
juxtacanalicular	O
connective	I:C0009780
tissue	I:C0009780
and	O
dilating	O
the	O
episcleral	O
veins	I:C0226616
,	O
which	O
led	O
to	O
redistribution	O
of	O
aqueous	O
outflow	O
through	O
a	O
larger	O
area	I:C0205146
of	O
the	O
IW	O
and	O
episcleral	B:C0226616
veins	I:C0226616
.	O

